Lycera Achieves First Milestone in Merck Research CollaborationLycera Corp., a biopharmaceutical company creating innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that it has reached the first milestone under its research collaboration with Merck, triggering a milestone payment.
New Use For Old Drug -- Arthritis, Cancer And More, VARI Says
Lycera Graduates from Incubator to North Campus Research ComplexLycera, a biopharmaceutical company and University of Michigan spinoff, plans to partner and collaborate with U-M faculty and students with a move to UM’s North Campus Research Complex.
Lycera Announces Research Collaboration with MerckThe Plymouth-based biopharmaceutical developer Lycera Corp. Thursday announced an exclusive research collaboration with pharma giant Merck to develop drug candidates that have the potential to treat major autoimmune diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and multiple sclerosis
Four New Psoriasis 'Hotspots' Identified By UM Geneticists
UM Researchers Get Large Collection Of Psoriasis Samples
Perrigo Files For New Generic